8-K: PROCEPT BioRobotics Q2 2025 Revenue Soars 48%

PROCEPT BioRobotics reported strong second-quarter 2025 financial results, with total revenue increasing 48% year-over-year and an upward revision of its full-year 2025 revenue guidance.

Summary

• Total revenue for the second quarter of 2025 was $79.2 million, marking a 48% increase compared to the prior year period.
• U.S. handpiece and consumables revenue reached $43.1 million, up 58% year-over-year.
• The company sold 51 robotic systems in the U.S. during the second quarter of 2025.
• International revenue grew by 69% to $9.6 million for the quarter.
• Gross margin improved to 65% in Q2 2025, up from 59% in the prior year period.
• Net loss for the quarter was $19.6 million, an improvement from a $25.6 million loss in the prior year period.
• Adjusted EBITDA loss improved to $8.0 million from $17.9 million in the prior year period.
• Full-year 2025 total revenue guidance was increased to $325.5 million, representing 45% growth over the prior year, up from the previous guidance of $323.0 million.
• Larry Wood was appointed as chief executive officer, effective September 2, 2025.

Sentiment

Score: 8

Explanation: Strong financial performance with significant revenue growth, improved profitability metrics (reduced losses), and an upward revision of full-year guidance indicate robust operational momentum and positive market reception for the company's products. The appointment of an experienced CEO further strengthens the outlook.

Positives

• Strong total revenue growth of 48% year-over-year to $79.2 million.
• Significant U.S. handpiece and consumables revenue growth of 58% to $43.1 million.
• Robust international revenue growth of 69% to $9.6 million.
• Improved gross margin to 65% due to improved operational efficiencies and higher average selling prices on U.S. robotic systems.
• Reduced net loss to $19.6 million from $25.6 million in the prior year period.
• Improved Adjusted EBITDA loss to $8.0 million from $17.9 million in the prior year period.
• Increased full-year 2025 revenue guidance to $325.5 million, indicating strong future outlook.
• Appointment of Larry Wood as CEO, bringing 40 years of leadership experience in the global medical technology industry.
• Expansion of U.S. robotic system install base to 595 systems as of June 30, 2025.

Negatives

• Continued net loss of $19.6 million for the quarter.
• Operating expenses increased to $73.9 million from $58.3 million in the prior year period, primarily due to expenses to expand the commercial organization, increased research and development, and increased general and administrative expenses.
• Adjusted EBITDA remains a loss of $8.0 million.
• Potential gross margin headwind of approximately $1.0 million to $2.0 million if global tariff rates remain at current levels.

Risks

• Potential gross margin headwind of approximately $1.0 million to $2.0 million if global tariff rates remain at current levels.
• Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results and expectations.
• Risks and uncertainties are described more fully in the 'Risk Factors' section of the company's filings with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K and subsequent quarterly reports on Form 10-Q.

Future Outlook

The company increased its full-year 2025 revenue guidance to approximately $325.5 million, representing 45% growth over the prior year, up from previous guidance of $323.0 million. It expects full-year 2025 gross margin to be approximately 64.5% and total operating expenses around $302.0 million, with an Adjusted EBITDA loss of approximately $35.0 million. The company believes its initiatives, including expanding Aquablation therapy utilization, deepening U.S. BPH hospital market penetration, accelerating WATER IV study enrollment, and advancing international commercial efforts, position it well for sustained growth and long-term value creation.

Management Comments

• "We delivered another strong quarter, with revenue growing 48% year-over-year, driven by robust global demand and continued procedural momentum."
• "Throughout the second quarter, we remained focused on expanding utilization of Aquablation therapy in the U.S., deepening penetration within the U.S. BPH hospital market, accelerating enrollment in the WATER IV prostate cancer study, and advancing our commercial efforts in key international markets."
• "We believe these initiatives position us well for sustained growth and long-term value creation."

Industry Context

PROCEPT BioRobotics operates in the surgical robotics and urology sector, specifically targeting Benign Prostatic Hyperplasia (BPH) treatment with its Aquablation therapy. The strong revenue growth and increased guidance suggest robust demand for innovative, minimally invasive surgical solutions in the urology market, aligning with broader trends towards advanced medical technology adoption and robotic-assisted procedures. The company's focus on expanding utilization and market penetration indicates a strategy to capture a larger share in the competitive medical device industry.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against.
• The reported 48% year-over-year revenue growth and 65% gross margin are strong indicators within the medical technology sector, which often sees high growth for innovative, high-margin products.
• The company's focus on expanding its installed base and increasing consumables revenue aligns with common strategies for medical device companies to drive recurring revenue streams post-system sale.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved financial performance, increased guidance, and experienced new CEO, potentially leading to increased share value.
• Patients: Continued advancement and expansion of Aquablation therapy offers an effective and safe treatment option for BPH.
• Employees: Expansion of the commercial organization suggests potential for job growth and stability.
• Hospitals/Customers: Increased system sales and installed base indicate growing adoption of the company's robotic systems.

Next Steps

• Continue expanding utilization of Aquablation therapy in the U.S.
• Deepen penetration within the U.S. BPH hospital market.
• Accelerate enrollment in the WATER IV prostate cancer study.
• Advance commercial efforts in key international markets.
• Host a conference call on August 6, 2025, to discuss Q2 2025 financial results.

Key Dates

Recommendation

The company demonstrates exceptional growth across all key revenue segments, significantly improved its gross margin, and narrowed its net and Adjusted EBITDA losses. The upward revision of full-year revenue guidance signals strong confidence in continued performance. The appointment of a highly experienced CEO further strengthens leadership. These factors collectively indicate robust operational momentum and strong future prospects, making it an attractive investment.

Keywords

Surgical Robotics, Urology, BPH Treatment, Aquablation Therapy, Medical Technology, Robotic Systems, Prostate Health, Healthcare, PROCEPT BioRobotics, PRCT